ConforMIS (NSDQ:CFMS) said today that it named Integra LifeSciences (NSDQ:IART) president Mark Augusti to succeed founder Dr. Phillip Lang as president & CEO effective Nov. 14.
Augusti, who led Integra’s Orthopedics & Tissue Technologies business, was previously CEO of Bioventus after a 9-year stint at corporate predecessor Smith & Nephew (NYSE:SNN).
“Mark Augusti’s experience and performance in a number of challenging roles was a significant factor in his selection as ConforMIS’ president & CEO. Mark has led teams that delivered strong growth during his tenure at Integra. In Integra’s most recently reported quarter, Mark’s Orthopedics & Tissue Technologies division revenue grew 38% from the prior-year period for both the quarter and six months ended June 30, 2016. Our board is looking forward to his commercial and operational leadership in unlocking the full value of our proprietary technology for customized joint implants,” chairman Kenneth Fallon III said in prepared remarks. “The board appreciates Dr. Lang’s contributions to ConforMIS as founder & CEO. Dr. Lang has been instrumental in building a great company, and we look forward to his continued contributions as a member of our board.”
“ConforMIS’ vision is ‘One Patient, One Implant,’ each customized and designed to restore the natural shape of a patient’s knee. The clinical benefits to the patient paired with the potential for economic savings to the hospital, when compared to leading off-the-shelf brands, have helped transform ConforMIS into a rapidly growing medical device company. Just a few weeks ago, we announced that we had sold over 50,000 customized knee implants since our inception, which represents a substantial increase over the 30,000 we had sold as of June of 2015 at the time of our IPO. This is a testament to our cutting-edge technology, and I am really excited about the prospects of ConforMIS as we move forward,” added Lang.
“I am extremely honored to be joining ConforMIS. I am impressed with this compelling technology and unique value proposition for the advancement of joint arthroplasty. From my discussions with surgeons that use ConforMIS customized implants, it is clear to me that the clinical benefits gained from ConforMIS’ customized implant systems are tremendous – not only for patients, but for doctors and hospitals as well. Surgeons that use ConforMIS implants are passionate about the results they are achieving. I look forward to working with Dr. Philipp Lang and the ConforMIS Board as we continue to move the company forward,” Augusti said.
Corindus Vascular Robotics bolsters medical affairs, commercial teams
Corindus Vascular Robotics (OTC:CVRS) said it named MedAxiom Consulting and Frederik Meijer Heart & Vascular Institute veteran Suzette Jaskie as VP of global medical affairs and tapped Jeff Lemaster, former marketing VP at C.R. Bard (NYSE:BCR), for the chief commercial officer role.
Skyline Medical interim CEO Schwartz steps down for interim chairmanship
Skyline Medical said this month that interim CEO Dr. Carl Schwartz stepped away from the corner office to accept the role of interim chairman. Skyline’s shareholders approved approved a reverse stock split last month, after announcing a joint venture with Electronic On-Ramp.
Xtant Medical names Wright Medical vet O’Connell as president
Xtant Medical (NYSE:XTNT) said it named Wright Medical (NSDQ:WMGI) veteran Carl O’Connell as president effective Oct. 6.